Tag: abbvie,
AbbVie sees near-term slowdown; looks prepared to tackle patent expiration
AbbVie, Inc. (NYSE: ABBV) has delivered yet another quarter of strong top-line and earnings performance but issued cautious guidance for fiscal 2023 citing an estimated drop in sales due to […]
The post AbbVie sees near-term slowdown; looks prepared to tackle patent expiration first appeared on AlphaStreet.
AbbVie (ABBV) Q4 2022 Earnings: Key financials and quarterly highlights
AbbVie (NYSE: ABBV) reported fourth quarter 2022 earnings results today. Worldwide net revenues increased 1.6% year-over-year to $15.1 billion. Net earnings attributable to AbbVie Inc. were $2.47 billion, or $1.38 […]
The post AbbVie (ABBV) Q4 2022 Earnings: Key financials and quarterly highlights first appeared on AlphaStreet.
BioMed X, AbbVie extend partnership to focus on immunology research
AbbVie sees Rinvoq, Skyrizi combined sales eclipsing Humira peak sales
: AbbVie cuts earnings forecast due to milestone payments
AbbVie expects IPR&D and milestones expense to impact Q4, full-year 2022 results
Cashing out in biotech in 2022: On-target predictions for AbbVie, Vertex and Genmab
J&J, Alkermes, AbbVie, others set to benefit from expanding schizophrenia drug market
AbbVie to create 70 new jobs with €60m Cork expansion
AbbVie already employs around 150 people in Carrigtwohill, and will be hiring for roles in sterile manufacturing, quality control and engineering.
Read more: AbbVie to create 70 new jobs with €60m Cork expansion